Pyxis Oncology completes MICVO enrollment, reports FY2025 net loss of $79.6M, names Interim CEO

Pyxis Oncology, Inc.

Completed target enrollment (n~40) for MICVO Phase 1 monotherapy dose expansion in 2L+ R/M HNSCC in Q1 2026.
Updated MICVO monotherapy data expected mid-2026; combination data with KEYTRUDA expected 2H26.
Appointed Thomas Civik as Interim CEO; added SVPs of Global Clinical Ops, IR/Capital Markets, and Global Program Leader.
Cash and investments $68.3M at Dec 31, 2025; expected cash runway into Q4 2026.
FY2025 net loss $79.6M ($1.28/diluted) vs $77.3M ($1.32) in 2024; revenue $13.9M from royalty sale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.